These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29979348)

  • 1. Tacrolimus-Induced Cholestatic Hepatitis in a Patient With Liver Transplant.
    González-Diéguez ML; Viso Vidal D; Mendoza Pacas GE; Houghton RF
    Transplantation; 2018 Oct; 102(10):e454-e456. PubMed ID: 29979348
    [No Abstract]   [Full Text] [Related]  

  • 2. Tacrolimus-Associated Jaundice.
    Pandey N; Gupta AK; Gupta S
    Am J Ther; 2018; 25(6):e723-e725. PubMed ID: 29672330
    [No Abstract]   [Full Text] [Related]  

  • 3. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
    Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus-induced cholestatic syndrome following pediatric liver transplantation and steroid-resistant graft rejection.
    Ganschow R; Albani J; Grabhorn E; Richter A; Burdelski M
    Pediatr Transplant; 2006 Mar; 10(2):220-4. PubMed ID: 16573611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modigraf administration through jejunostomy in liver transplant recipient: case report.
    Marente VC; Gomez LM; Martinez JG; Bernal-Bellido C; Suárez-Artacho G; Alamo-Martínez JM; Barrera-Pulido L; Serrano-Díaz-Canedo J; Padillo-Ruiz FJ; Gómez-Bravo MA
    Transplant Proc; 2013; 45(10):3670-1. PubMed ID: 24314992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center.
    Hu AB; Wu LW; Tai Q; Zhu XF; He XS
    J Dig Dis; 2013 Jan; 14(1):38-44. PubMed ID: 23134408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
    Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
    Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome.
    Catalano G; De Simone P; Mazzoni A; Ghinolfi D; Coletti L; Filipponi F
    Transpl Int; 2014 Sep; 27(9):e84-6. PubMed ID: 24606320
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis B immunoglobulin-induced hypercoagulability complicating liver transplantation necessitating ECMO, rescue hepatectomy, and retransplantation.
    Frank PN; Sharma VV; Gereboff A; Guindi M; Kim IK; Kariger R
    J Clin Anesth; 2018 Feb; 44():64-65. PubMed ID: 29149732
    [No Abstract]   [Full Text] [Related]  

  • 10. Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection.
    Jain A; Constantinescu S; Maloo M; Mukerji AN; Karachristos A; Lau K; Di Carlo A
    Transplantation; 2014 Oct; 98(7):e68-70. PubMed ID: 25285953
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of Tacrolimus-Induced Toxicity With Normal Serum Levels After Liver Transplant.
    Majid Z; Khan SA; Hanif FM; Laeeq M; Tasneem AA; Luck NH; Mubarak M
    Exp Clin Transplant; 2024 Jan; 22(Suppl 1):338-341. PubMed ID: 38385422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of chronic rejection after treatment failure with FK506 and RS61443.
    Roberts JP; Lake JR; Hebert M; Nikolai B; Ascher NL; Ferrell LD
    Transplantation; 1993 Oct; 56(4):1021-3. PubMed ID: 7692634
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of tacrolimus-associated food allergy after liver transplantation.
    Obayashi N; Suzuki M; Yokokura T; Naritaka N; Nakano S; Ohtsuka Y; Sugo H; Kawasaki S; Shimizu T
    Pediatr Int; 2015 Dec; 57(6):1205-7. PubMed ID: 26541649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study.
    Lorho R; Hardwigsen J; Dumortier J; Pageaux GP; Durand F; Bizollon T; Blanc AS; Di Giambattista F; Duvoux C
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35(6-7):482-8. PubMed ID: 21530445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P; Samonakis D; Cholongitas E; Patch D; O'Beirne J; Dhillon AP; Rolles K; McCormick A; Hayes P; Burroughs AK
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of progressive liver fibrosis in pediatric liver transplants: A review of current evidence.
    George M; Paci P; Taner T
    World J Gastroenterol; 2020 May; 26(17):1987-1992. PubMed ID: 32536769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.